JIPOAd
  • Users Online: 198
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Most popular articles (Since November 13, 2017)

 
 
  Archives   Most popular articles   Most cited articles
 
Show all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
EDITORIAL
Being realistic and optimistic in curing cancer
Aung Naing
October-December 2018, 1(2):53-55
DOI:10.4103/JIPO.JIPO_20_18  
  1,454 330 -
ORIGINAL ARTICLES
Erlotinib in patients with advanced non-small cell lung cancer in Middle Eastern population
Abdul Rahman Jazieh, Turki M Fayea, Mervat Mahrous, Tarek Darwish, Essam Fawzi, Ashwaq A Alolayan, Nagham Sheblaq, Mohammed Alkaiyat, Yosra Ali
July-September 2018, 1(1):19-25
DOI:10.4103/JIPO.JIPO_2_18  
  1,331 93 -
REVIEW ARTICLES
Pneumonitis after precision oncology therapies: A concise review
Akash Jain, Vickie R Shannon, Ajay Sheshadri
July-September 2018, 1(1):26-37
DOI:10.4103/JIPO.JIPO_9_18  
  1,004 135 -
Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event
Abdulrazzak Zarifa, Mohammed Salih, Juan Lopez-Mattei, Hun Ju Lee, Cezar Iliescu, Saamir Hassan, Nicolas Palaskas, Jean-Bernard Durand, Elie Mouhayar, Joseph Kim, Peter Kim
October-December 2018, 1(2):68-77
DOI:10.4103/JIPO.JIPO_15_18  
  904 134 -
ORIGINAL ARTICLES
The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes
Hamzah Abu-Sbeih, Tenglong Tang, Faisal Shaukat Ali, Daniel Hartman Johnson, Wei Qiao, Adi Diab, Yinghong Wang
July-September 2018, 1(1):7-18
DOI:10.4103/JIPO.JIPO_12_18  
  783 130 -
Pembrolizumab in advanced gastrointestinal malignancies with defective dna mismatch repair: A case series
David D Stenehjem, Courtney C Cavalieri, Eric Swanson, Benjamin Solomon, Jonathan Whisenant, Dao Tran, John Weis, G Weldon Gilcrease, Sunil Sharma, Ignacio Garrido-Laguna
July-September 2018, 1(1):1-6
DOI:10.4103/JIPO.JIPO_5_18  
  801 103 -
REVIEW ARTICLES
Understanding the toxicity of cancer immunotherapies: Use of patient-reported outcomes
Tito R Mendoza
July-September 2018, 1(1):38-45
DOI:10.4103/JIPO.JIPO_10_18  
  732 145 -
Personalized cancer immunotherapy: Today's challenge and tomorrow's promise
Malaka Ameratunga, Wen Xu, Juanita Lopez
October-December 2018, 1(2):56-67
DOI:10.4103/JIPO.JIPO_13_18  
  706 106 -
CASE REPORTS
Bronchiolitis obliterans after combination immunotherapy with pembrolizumab and ipilimumab
Amulya Balagani, Muhammad H Arain, Ajay Sheshadri
July-September 2018, 1(1):49-52
DOI:10.4103/JIPO.JIPO_8_18  
  525 45 -
Toxic epidermal necrolysis during cotherapy with ipilimumab and nivolumab
Shelby L Kubicki, Macartney E Welborn, Anisha B Patel
October-December 2018, 1(2):78-81
DOI:DOI: 10.4103/JIPO.JIPO_7_18  
  504 63 -
ORIGINAL ARTICLES
The Study of Druggable Targets in Nonsquamous Non-Small-Cell Lung Cancer in the Middle East and North Africa
Abdul Rahman Jazieh, Adda Bounedjar, Fouad Al Dayel, Shamayel Fahem, Arafat Tfayli, Kakil Rasul, Hassan Jaafar, Mohammad Jaloudi, Turki Al Fayea, Hatim Q Al Maghrabi, Hanaa Bamefleh, Khaled Al Kattan, Blaha Larbaoui, Taha Filali, Hamed Al Husaini, Yosra Ali, in collaboration with the Arab Collaborative Hematology Oncology Group (ACHOG)
0, 0(0):0-0
DOI:10.4103/JIPO.JIPO_22_18  
  525 12 -
CASE REPORTS
Pyoderma gangrenosum following initiation of immune checkpoint inhibitor therapy
Macartney E Welborn, Shelby L Kubicki, Anisha B Patel
October-December 2018, 1(2):82-84
DOI:10.4103/JIPO.JIPO_11_18  
  403 55 -
Inflammatory colitis after treatment of melanoma with talimogene laherparepvec (T-VEC)
Jennifer Gardner, Teresa Hyun, Gideon Steinbach, John Thompson
July-September 2018, 1(1):46-48
DOI:10.4103/JIPO.JIPO_3_18  
  412 27 -
EDITORIAL
Optimizing Precision Oncology and Immunotherapy Strategies: Moving into the Next Stage of Cancer Medicine
Phoebe Lewis, Timothy A Yap
0, 0(0):0-0
DOI:10.4103/JIPO.JIPO_26_18  
  24 11 -
SPECIAL ARTICLE
5th Annual immuno-oncology 360° conference: What to expect, february, 6–8, 2019, crown plaza times square, New York City, NY
Kate Woda
0, 0(0):0-0
DOI:10.4103/2590-017X.249502  
  24 9 -
REVIEW ARTICLES
Extracellular signal-regulated kinase (ERK) inhibitors in oncology clinical trials
Haelee M Chin, David K Lai, Gerald S Falchook
0, 0(0):0-0
DOI:10.4103/JIPO.JIPO_17_18  
  18 5 -
CASE REPORTS
Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment
Cynthia Nguyen Tran, Hamzah Abu-Sbeih, Wenyi Luo, Yang Lu, Yinghong Wang
0, 0(0):0-0
DOI:10.4103/JIPO.JIPO_18_18  
  8 1 -